Heron Therapeutics (NASDAQ:HRTX) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05), Briefing.com reports. The business had revenue of $19.79 million for the quarter, compared to analyst estimates of $19.84 million. Heron Therapeutics had a negative return on equity of 112.35% and a negative net margin of 411.41%. The business’s quarterly revenue was up 130.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.77) earnings per share.
HRTX traded down $0.56 during trading on Thursday, reaching $30.55. The stock had a trading volume of 490,520 shares, compared to its average volume of 984,231. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 8.37 and a beta of 1.45. Heron Therapeutics has a 1-year low of $14.95 and a 1-year high of $42.90.
In other Heron Therapeutics news, VP Kimberly Manhard sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $32.07, for a total value of $192,420.00. Following the completion of the sale, the vice president now directly owns 6,000 shares in the company, valued at $192,420. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kevin C. Tang sold 2,695,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total value of $96,346,250.00. The disclosure for this sale can be found here. Insiders sold 2,701,494 shares of company stock valued at $96,553,796 over the last 90 days. 16.20% of the stock is currently owned by insiders.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Recommended Story: What are the risks of holding treasury bonds?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.